Literature DB >> 15979242

Delayed inhibition of Nogo-A does not alter injury-induced axonal sprouting but enhances recovery of cognitive function following experimental traumatic brain injury in rats.

P M Lenzlinger1, S Shimizu, N Marklund, H J Thompson, M E Schwab, K E Saatman, R C Hoover, F M Bareyre, M Motta, A Luginbuhl, R Pape, A K Clouse, C Morganti-Kossmann, T K McIntosh.   

Abstract

Traumatic brain injury causes long-term neurological motor and cognitive deficits, often with limited recovery. The inability of CNS axons to regenerate following traumatic brain injury may be due, in part, to inhibitory molecules associated with myelin. One of these myelin-associated proteins, Nogo-A, inhibits neurite outgrowth in vitro, and inhibition of Nogo-A in vivo enhances axonal outgrowth and sprouting and improves outcome following experimental CNS insults. However, the involvement of Nogo-A in the neurobehavioral deficits observed in experimental traumatic brain injury remains unknown and was evaluated in the present study using the 11C7 monoclonal antibody against Nogo-A. Anesthetized, male Sprague-Dawley rats were subjected to either lateral fluid percussion brain injury of moderate severity (2.5-2.6 atm) or sham injury. Beginning 24 h post-injury, monoclonal antibody 11C7 (n=17 injured, n=6 shams included) or control Ab (IgG) (n=16 injured, n=5 shams included) was infused at a rate of 5 microl/h over 14 days into the ipsilateral ventricle using osmotic minipumps connected to an implanted cannula. Rats were assessed up to 4 weeks post-injury using tests for neurological motor function (composite neuroscore, and sensorimotor test of adhesive paper removal) and, at 4 weeks, cognition was assessed using the Morris water maze. Hippocampal CA3 pyramidal neuron damage and corticospinal tract sprouting, using an anterograde tracer (biotinylated dextran amine), were also evaluated. Brain injury significantly increased sprouting from the uninjured corticospinal tract but treatment with monoclonal antibody 11C7 did not further increase the extent of sprouting nor did it alter the extent of CA3 cell damage. Animals treated with 11C7 showed no improvement in neurologic motor deficits but did show significantly improved cognitive function at 4 weeks post-injury when compared with brain-injured, IgG-treated animals. To our knowledge, the present findings are the first to suggest that (1) traumatic brain injury induces axonal sprouting in the corticospinal tract and this sprouting may be independent of myelin-associated inhibitory factors and (2) that post-traumatic inhibition of Nogo-A may promote cognitive recovery unrelated to sprouting in the corticospinal tract or neuroprotective effects on hippocampal cell loss following experimental traumatic brain injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979242     DOI: 10.1016/j.neuroscience.2005.04.048

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  25 in total

1.  Selective temporal and regional alterations of Nogo-A and small proline-rich repeat protein 1A (SPRR1A) but not Nogo-66 receptor (NgR) occur following traumatic brain injury in the rat.

Authors:  Niklas Marklund; Carl T Fulp; Saori Shimizu; Rishi Puri; Asenia McMillan; Stephen M Strittmatter; Tracy K McIntosh
Journal:  Exp Neurol       Date:  2006-01       Impact factor: 5.330

2.  Microwave & Magnetic (M2) Proteomics of a Mouse Model of Mild Traumatic Brain Injury.

Authors:  Teresa M Evans; Holly Van Remmen; Anjali Purkar; Swetha Mahesula; J Al Gelfond; Marian Sabia; Wenbo Qi; Ai-Ling Lin; Carlos A Jaramillo; William E Haskins
Journal:  Transl Proteom       Date:  2014-06-01

Review 3.  Genetic manipulation of cell death and neuroplasticity pathways in traumatic brain injury.

Authors:  Kathleen M Schoch; Sindhu K Madathil; Kathryn E Saatman
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  Increased hippocampal NgR1 signaling machinery in aged rats with deficits of spatial cognition.

Authors:  Heather D VanGuilder Starkey; William E Sonntag; Willard M Freeman
Journal:  Eur J Neurosci       Date:  2013-02-26       Impact factor: 3.386

5.  Hippocampal expression of myelin-associated inhibitors is induced with age-related cognitive decline and correlates with deficits of spatial learning and memory.

Authors:  Heather D Vanguilder; Georgina V Bixler; William E Sonntag; Willard M Freeman
Journal:  J Neurochem       Date:  2012-02-10       Impact factor: 5.372

6.  Genetic deletion and pharmacological inhibition of Nogo-66 receptor impairs cognitive outcome after traumatic brain injury in mice.

Authors:  Anders Hånell; Fredrik Clausen; Maria Björk; Kristine Jansson; Ola Philipson; Lars N G Nilsson; Lars Hillered; Paul H Weinreb; Daniel Lee; Tracy K McIntosh; David A Gimbel; Stephen M Strittmatter; Niklas Marklund
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

7.  Hippocampal dysregulation of synaptic plasticity-associated proteins with age-related cognitive decline.

Authors:  Heather D VanGuilder; Julie A Farley; Han Yan; Colleen A Van Kirk; Matthew Mitschelen; William E Sonntag; Willard M Freeman
Journal:  Neurobiol Dis       Date:  2011-04-01       Impact factor: 5.996

8.  The contribution of gliosis to diffusion tensor anisotropy and tractography following traumatic brain injury: validation in the rat using Fourier analysis of stained tissue sections.

Authors:  Matthew D Budde; Lindsay Janes; Eric Gold; Lisa Christine Turtzo; Joseph A Frank
Journal:  Brain       Date:  2011-07-15       Impact factor: 13.501

Review 9.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 10.  Chronic Histopathological and Behavioral Outcomes of Experimental Traumatic Brain Injury in Adult Male Animals.

Authors:  Nicole D Osier; Shaun W Carlson; Anthony DeSana; C Edward Dixon
Journal:  J Neurotrauma       Date:  2015-04-15       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.